SOPHiA GENETICS SA (NASDAQ:SOPH – Get Free Report) insider Philippe Menu sold 7,393 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $5.16, for a total value of $38,147.88. Following the completion of the transaction, the insider owned 233,387 shares of the company’s stock, valued at $1,204,276.92. This trade represents a 3.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Philippe Menu also recently made the following trade(s):
- On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.50, for a total transaction of $27,500.00.
- On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total value of $24,750.00.
- On Monday, April 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.82, for a total value of $24,100.00.
- On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.20, for a total transaction of $3,161.60.
- On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total transaction of $7,936.00.
- On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $20,944.00.
- On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total value of $17,433.00.
- On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,152.94.
- On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.
SOPHiA GENETICS Stock Performance
NASDAQ:SOPH opened at $5.82 on Friday. The business’s 50-day moving average price is $5.16 and its two-hundred day moving average price is $4.98. SOPHiA GENETICS SA has a twelve month low of $2.92 and a twelve month high of $6.30. The stock has a market cap of $488.24 million, a P/E ratio of -11.19 and a beta of 0.96. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of SOPH. Silverberg Bernstein Capital Management LLC lifted its holdings in shares of SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after purchasing an additional 4,155 shares during the last quarter. Green Alpha Advisors LLC boosted its position in shares of SOPHiA GENETICS by 10.8% in the 4th quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock worth $213,000 after purchasing an additional 4,444 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after buying an additional 6,205 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after buying an additional 9,800 shares during the last quarter. Finally, First Dallas Securities Inc. bought a new position in SOPHiA GENETICS during the 1st quarter valued at approximately $50,000. 31.59% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on the stock. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $7.50.
Get Our Latest Stock Report on SOPH
About SOPHiA GENETICS
SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.
The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.
Featured Articles
- Five stocks we like better than SOPHiA GENETICS
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.
